|
Latest News |
|
|
TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
2009/12/07
More»
Excellent Stem Cell Mobilization and Safety Profile for TG-0054
2009/09/28
More»
TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
2009/01/20
More»
TaiGen Announces Presentation of Nemonoxacin at the Joint Meeting of ICAAC/IDSA
2008/10/20
More»
TaiGen Announces Positive Data From the Phase II Study of Nemonoxacin (TG-873870) in Community-Acquired Pneumonia
2008/04/07
More»
TaiGen Initiates Phase I Trial of the Stem Cell Mobilizer TG-0054
2008/04/07
More» |
|
TaiGen Biotechnology Co., Ltd.
7F, 138 Shin Ming Rd. Neihu Dist.,
Taipei, Taiwan 114 R.O.C.
Tel: 886-2-81777072
886-2-27901861
Fax: 886-2-27963606
service@taigenbiotech.com.tw
TaiGen Biopharmaceuticals Co. (Beijing), Ltd.
Suite 2209, A Tower, FULL LINK Building
No. 18 Chaoyangmenwaidajie,
Beijing 100020, China
Tel: 86-10-65885166
Fax: 86-10-65885167
For investor relations, please contact:
PJ (Joe) Hsueh, Director of Operations
Tel. 886-2-81777072 ext 1704
886-933-917-804
pjhsueh@taigenbiotech.com.tw
For business development opportunities, please contact:
Dr. John Jin, VP Global Business Development
Tel: 886-2-2790-1861
johnjin@taigenbiotech.com.tw
Location maps:
Taipei Office
View Larger Map
Beijing Office
View Larger Map
|
|
|
